Idarubicin prevents DNA from unwinding by interfering with the enzyme topoisomerase II. Idarubicin belongs to the family called antitumor antibiotics. Idarubicin inhibits the proliferation of NALM-6 cells with an IC50 of 12 nM. Idarubicin has significant cytotoxic activity against multicellular spheroids, comparable to the antiproliferative effects on monolayer cells. Idarubicin is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia. Idarubicin plus Decitabine and cytarabine has entered in a phase II clinical trial in the treatment of adult acute myeloid leukemia, and adult acute monoblastic leukemia, refractory anemia with excess blasts.
ACS Biomater Sci Eng. 2021 Dec 21.
Strategies to Maximize Anthracycline Drug Loading in Albumin Microbubbles
Idarubicin purchased from AbMole
|Cell lines||K562S and K562R cells|
|Preparation method||MTT assay
K562S and K562R cells were cultured in a 96-well plate (SPL) at a density of 1 × 104 cells in 100 μL of medium per well and treated with the indicated concentration of Imatinib or the AGM130 compound for 72 h. To measure the cell viability, the EZ-Cytox Cell Viability Assay kit was used. Ten microliters of MTT reagent was evenly treated in each well and incubated at 37 ◦C and 5% CO2 for 6 h. At the end of the incubation, the MTT factors of incubated cells in the plate were measured at the 450 nm wavelength using an ELISA detector.
|Incubation time||72 h|
|Animal models||Imatinibresistant K562 cells xenograft model using BALB/c nude mice|
|Solubility (25°C)||DMSO 50 mg/mL|
|Storage||2-8°C, dry, protect from light, sealed|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Kim WS, et al. Leuk Res. 5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
 Ravandi F, et al. Cancer. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
 Cortes J, et al. Cancer. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.
 Mandelli F, et al. J Clin Oncol. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
 Strolin Benedetti M, et al. Xenobiotica. Stereoselectivity of idarubicin reduction in various animal species and humans.
|Related Topoisomerase Products|
9-Aminocamptothecin (9-amino-CPT) is a topoisomerase I inhibitor with potent anticancer activity. 9-Aminocamptothecin inhibits PC-3, PC-3M, DU145, and LNCaP cells with IC50 values of 34.1, 10, 6.5, and 8.9 nM, respectively after 96 h exposure.
Rubitecan is a topoisomerase I inhibitor extracted from the bark and leaves of the Camptotheca acuminata tree, which is native to China. Rubitecan is an oral camptothecin with antitumour activity.
10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor with potent anti-tumor activity.
WAY-272160 is a inhibitory activities for topoisomerase II and HER2
Gatifloxacin (AM-1155, CG5501, BMS-206584, PD135432) hydrochloride is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases with IC50 of 13.8 μg/ml and 0.109 μg/ml for S. aureus topoisomerase IV and E. coli DNA gyrase, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.